Lasofoxifene tartrate

• CAT Number: I002447
• CAS Number: 190791-29-8
• Molecular Formula: C₂₈H₃₁NO₂.C₄H₆O₆
• Molecular Weight: 563.6
• Purity: ≥95%
• Synonyms: (5R,6S)-5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol, (2S,3S)-2,3-dihydroxybutanedioate
• Target: Estrogen Receptor/ERR
• Solubility: DMSO: ≤ 6 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1
• InChIKey: INEHJXCWEVNEDZ-LUDNRVPPSA-N
• SMILES: C1CCN(C1)CCOC2=CC=C(C=C2)C3C(CCC4=C3C=CC(=C4)O)C5=CC=CC=C5.C(C(C(=O)O)O)(C(=O)O)O

Lasofoxifene tartrate (Cat.No:I002447) is a selective estrogen receptor modulator (SERM) used in the treatment and prevention of osteoporosis in postmenopausal women. It works by binding to estrogen receptors, exerting estrogenic effects on bone tissue and reducing bone loss. Lasofoxifene tartrate has also shown potential in reducing the risk of certain types of breast cancer.

Reference

[1]. Andersson A, et al. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2015 Sep 30. pii: kev355.